Podcast
OnFocus Podcast: Michael Hoey
April 27, 2022

Francis Medical Founder and Chief Technology Officer, Michael Hoey, was recently featured on OnFocus, a podcast by The Focal Therapy Clinic in the UK.
Click below to hear Michael talk about his personal journey into discovering and developing water vapor therapy for treating the prostate and why he’s so committed to innovating in this space.
Original episode post and transcript
Supplemental Article: Key Trends Driving Progress in Focal Therapy
Learn more about water vapor therapy
Recent Posts
Francis Medical Announces Publication of VAPOR 2 Pivotal Trial Results in The Journal of Urology
websites2026-07-01T12:09:06-05:00June 30th, 2026|
MAPLE GROVE, Minn., June 30, 2026 – Francis Medical, Inc., a medical device company dedicated to advancing minimally invasive therapies for urological cancers, today announced the publication of the initial report from its VAPOR 2 pivotal clinical study in The Journal of Urology, one of the world’s leading peer-reviewed urology journals.
University of Chicago Urologist Performs First Commercial Vanquish® Water Vapor Ablation Procedure in the State
websites2026-07-01T16:11:13-05:00May 28th, 2026|
Chicago, IL [May 28, 2026] – Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first commercial Vanquish® Water Vapor Ablation procedure in the Chicago metropolitan area, marking a significant milestone for patients in the region seeking minimally invasive prostate treatment options.
Francis Medical Announces Further Expansion of Commercial Vanquish® Procedures to Ablate Prostate Tissue
websites2026-07-01T12:20:14-05:00May 6th, 2026|
Minneapolis, MN [May 06, 2026] – Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Naveen Kella, MD, of The Urology Place has successfully completed the first commercial procedures in San Antonio, Texas, using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue. Dr. Kella, who was also a clinical investigator in the VAPOR 2 pivotal study, performed the procedures on patients diagnosed with localized prostate cancer at Huebner Ambulatory Surgery Center.




Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.